Lorena Pérez-Amill
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lorena Pérez-Amill has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Beatriz Martin-Antonio
Centro de Terapias Avanzadas, Instituto de Salud Carlos III, Madrid, Spain
112 shared publications - Manel Juan
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
111 shared publications - Álvaro Urbano-Ispizua
Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (FCRB-IDIBAPS), 08036 Barcelona, Spain
111 shared publications - Aina Oliver-Caldés
Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona Barcelona Spain
110 shared publications - Carlos Fernández de Larrea
Hospital Clínic de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
110 shared publications - Valentín Ortiz-Maldonado
Hospital Clinic, Barcelona, Spain
110 shared publications
Latest Publications
- Open Access
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Parameters used for the clinical data-based model.
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Parameters used for the clinical data-based model.
- Open Access
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 17 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure S17 highlights statistically significant differences in fecal metabolite abundance between multiple myeloma patients and healthy donors. This figure presents mean fecal metabolite abundance ±SD for various metabolites, with individual dots representing MM patients or healthy donors, and statistical significance indicated by asterisks based on Mann-Whitney test results.
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 17 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure S17 highlights statistically significant differences in fecal metabolite abundance between multiple myeloma patients and healthy donors. This figure presents mean fecal metabolite abundance ±SD for various metabolites, with individual dots representing MM patients or healthy donors, and statistical significance indicated by asterisks based on Mann-Whitney test results.
- Open Access
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 22 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure S22 illustrates the association between post-infusion systemic short-chain fatty acid (SCFA) levels and treatment response in multiple myeloma (MM) patients. This figure analyzes serum SCFA levels at both 100 and 180 days post–CAR T-cell infusion, comparing patients who achieved complete response to those who did not.
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 22 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure S22 illustrates the association between post-infusion systemic short-chain fatty acid (SCFA) levels and treatment response in multiple myeloma (MM) patients. This figure analyzes serum SCFA levels at both 100 and 180 days post–CAR T-cell infusion, comparing patients who achieved complete response to those who did not.
- Open Access
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 13 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
SCFA evaluation in serum of MM patients from the first cohort at the apheresis day, using gas chromatography-mass spectrometry methodology
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 13 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
SCFA evaluation in serum of MM patients from the first cohort at the apheresis day, using gas chromatography-mass spectrometry methodology
- Open Access
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Distribution of patients that donated at least one stool sample to the study in cohort 1 and were treated.
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Distribution of patients that donated at least one stool sample to the study in cohort 1 and were treated.
- Open Access
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 13 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure S13 investigates the effects of a FOS-diet on CAR T cells in an in vivo rechallenge model. The figure displays tumor growth monitored by bioluminescent imaging, shows absolute peripheral blood CD45+ T-cell counts post-tumor rechallenge, and includes a Kaplan-Meier survival curve for tumor-bearing mice treated with CAR T cells, with or without FOS feeding.
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 13 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure S13 investigates the effects of a FOS-diet on CAR T cells in an in vivo rechallenge model. The figure displays tumor growth monitored by bioluminescent imaging, shows absolute peripheral blood CD45+ T-cell counts post-tumor rechallenge, and includes a Kaplan-Meier survival curve for tumor-bearing mice treated with CAR T cells, with or without FOS feeding.
- Open Access
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Linear regression analysis identifying independent predictors of CD4+ central memory level
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Linear regression analysis identifying independent predictors of CD4+ central memory level
- Open Access
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Main characteristics of the patients, response and safety
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Main characteristics of the patients, response and safety
- Open Access
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 16 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Relative quantification of inosine in serum of MM patients from the first cohort at different time points, using the targeted UHPLC-MS methodology. V1: Apheresis day, V11: 28 days post CAR-T infusion, 12M: 12 months post CAR-T infusion, UHPLC-MS: Ultra High-Performance Liquid Chromatography Mass Spectrometry
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 16 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Relative quantification of inosine in serum of MM patients from the first cohort at different time points, using the targeted UHPLC-MS methodology. V1: Apheresis day, V11: 28 days post CAR-T infusion, 12M: 12 months post CAR-T infusion, UHPLC-MS: Ultra High-Performance Liquid Chromatography Mass Spectrometry
- Open Access
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 18 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure S18 presents LDA scores that indicate differences in taxonomic abundance based on toxicity profiles in multiple myeloma (MM) patients. The figure shows comparisons between patients with and without cytokine release syndrome (CRS), and further differentiates by CRS grade, specifically highlighting those with grade 2 CRS.
- 3 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 18 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma
Supplementary Figure S18 presents LDA scores that indicate differences in taxonomic abundance based on toxicity profiles in multiple myeloma (MM) patients. The figure shows comparisons between patients with and without cytokine release syndrome (CRS), and further differentiates by CRS grade, specifically highlighting those with grade 2 CRS.